Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Accumulated Expenses (2021 - 2025)

PAVmed has reported Accumulated Expenses over the past 5 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $2.5 million for Q4 2025, down 51.97% from a year ago — trailing twelve months through Dec 2025 was $2.5 million (down 51.97% YoY), and the annual figure for FY2025 was $2.5 million, down 51.97%.
  • Accumulated Expenses for Q4 2025 was $2.5 million at PAVmed, down from $2.7 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for PAVM hit a ceiling of $6.8 million in Q2 2024 and a floor of $1.1 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $3.2 million (2022), compared with a mean of $3.6 million.
  • Biggest five-year swings in Accumulated Expenses: soared 208.74% in 2022 and later crashed 65.69% in 2025.
  • PAVmed's Accumulated Expenses stood at $4.3 million in 2021, then decreased by 13.01% to $3.7 million in 2022, then surged by 78.84% to $6.6 million in 2023, then decreased by 21.88% to $5.2 million in 2024, then crashed by 51.97% to $2.5 million in 2025.
  • The last three reported values for Accumulated Expenses were $2.5 million (Q4 2025), $2.7 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.